Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer


The purpose of this trial is to study the effect – in terms of time to progression and overall survival – of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.

Full Title of Study: “A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: July 2008


  • Drug: Bicalutamide
    • 150mg daily
  • Drug: Placebo
    • once daily

Arms, Groups and Cohorts

  • Experimental: 1
  • Placebo Comparator: 2

Clinical Trial Outcome Measures

Primary Measures

  • Time to clinical progression
    • Time Frame: Throughout study period
  • Overall patient survival
    • Time Frame: Throughout study period

Secondary Measures

  • Time to treatment failure
    • Time Frame: Throughout study period
  • Serum prostate-specific antigen
    • Time Frame: Initial study period up to 2006 amended protocol
  • Tolerability in terms of adverse events and laboratory parameters
    • Time Frame: Throughout study period

Participating in This Clinical Trial

Inclusion Criteria

  • Prostate cancer in the early stage of disease
  • Prostate removed and/or radiation therapy to the prostate area

Exclusion Criteria

  • Previous systemic therapy for prostate cancer
  • Previous history of another form of cancer (not prostate) within 5 years of study start.

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • AstraZeneca
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • William See, Principal Investigator, Medical College of Wisconsin
    • David G. McLeod, Principal Investigator, Walter Reed Army Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.